Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02296918
Title ACP-196 in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Acerta Pharma BV
Indications

prolymphocytic leukemia

chronic lymphocytic leukemia

chronic lymphocytic leukemia/small lymphocytic lymphoma

Therapies

Acalabrutinib + Obinutuzumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.